Evidence map›Paper›PMID 36820177›Full record

ArticleHeliyon2023

Ocular surface reconstruction of Steven Johnson syndrome / toxic epidermal necrolysis affected eye - A case report.

Tzu-Yun Tsai, Hou-Tai Chang, Shao-Wei Weng, Chan-Ching Chu, Yi-Chun Wang, Zhanqi Zhao, Elsa Lin-Chin Mai

Open access · goldAbstract readCase Reports
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Tzu-Yun TsaiDepartment of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Hou-Tai ChangCenter of Hyperbaric Oxygen, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Shao-Wei WengDepartment of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Chan-Ching ChuDepartment of Chest Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Yi-Chun WangDepartment of Chest Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Zhanqi ZhaoDepartment of Biomedical Engineering, Fourth Military Medical University, Xi'an, China.
Elsa Lin-Chin MaiDepartment of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Far Eastern Memorial Hospital · TWFurtwangen University · DEYuanpei University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Toxic epidermal necrolysis (TEN), also known as Steven Johnson syndrome (SJS), is a devastating disease. Patients develop blindness and symblepharon despite multiple reconstructive surgeries. We report a case of SJS/TEN with ocular involvement where treatment with hyperbaric oxygen therapy (HBOT) resulted in a significant improvement in the visual acuity after surgery. Case presentation: A woman with SJS/TEN with severe ocular complication (SOC) had limbal stem cell deficiency and symblepharon of the superior and inferior fornix. Pannus grew over her cornea, reducing the vision to counting finger. The symblepharon produced shortening of the fornix, causing entropion. The in-turned eyelid caused her eyelashes to rub against the cornea, causing great damage to the ocular surface. Limbal stem cell deficiency led to the loss of normal corneal morphology and invasion of the pannus onto the central visual axis, resulting in poor vision. She experienced ocular inflammation for 3 months before transfer to our hospital for admission. Ophthalmic examination showed bilateral corneal opacity with conjunctivalization, and inferior and superior fornix shortening. Symblepharon-lysis with amniotic membrane transplantation was attempted but the outcome was poor, with recurrence of superior scaring and symblepharon. She finally underwent major reconstructive surgery with allogeneic limbal stem cell transplantation with her sister as the donor, autologous minor salivary gland transplantation, and oral buccal mucosa flap transplant. HBOT was given daily post-surgery for supporting the grafts and suppressing inflammation. After 17 HBOT sessions and 3 months of autoserum drops, her left eye vision increased from the initial counting finger to 0.4 due to the successful growth of the corneal epithelium from the donor corneal limbal cell line. When a scleral contact lens which vaulted over the corneal limbal area was fitted, her vision improved to 0.8 due to redressal of high order aberration and astigmatism from the cornea scar. Conclusion: After major reconstruction of the ocular surface with multiple cell type transplants, including limbal stem cells, minor salivary gland acinar cells, and oral mucosa cells, HBOT proved useful in supporting the graft uptake and oxygenation of the donor tissues, enabling fast recovery of the grafts and cell functioning, with eventual return of the working vision of the patient.

Indexed as

AMT, amniotic membrane transplantationCase reportCLAL, conjunctival limbal allograftCLAU, conjunctival limbal autograftCLET, Cultivated limbal epithelial transplantationHBOT, Hyperbaric oxygen therapyHLA typing, human leucocyte antigen typingHyperbaric oxygen therapyLimbal stem cell deficiencyLimbal stem cell transplantationlr-CLAL, living-related conjunctival limbal allograftLSCD, Limbal stem cell deficiencyMinor salivary gland transplantOral buccal mucosa flap transplantationSJS, Steven Johnson syndromeSOC, severe ocular complicationStevens-Johnson syndromeTEN, toxic epidermal necrolysisToxic epidermal necrolysis

Identifiers

PMID36820177
PMCPMC9938410
OpenAlexW4312159226

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.